Cancer is one of the leading causes of mortality for 1 in 7 individuals globally. It is globally acknowledged that early diagnosis and screening are of major importance for improving the likelihood of recovery. However, given the time-consuming, costly, and invasive nature of existing methods for cancer screening, patients often do not prefer these services. Researchers are focused on developing reliable, non-invasive, and fast diagnostic tools that can be directly used by the local physicians for point-of-care cancer screening. Incorporation of various biomarkers into point-of-care cancer screening devices is expected to potentially reduce the strain experienced by various healthcare systems and hospitals. Essentially, point-of-care cancer screening is capable of enhancing the well-being of patients and could further lead to a reduction in cancer-related deaths, globally. Point-of-care cancer screening tests are being miniaturized and simplified, for reducing the overall cost of equipment, materials, and personnel costs. The use of biosensor technologies and “lab-on-a-chip” has facilitated this change, making point-of-care cancer screening possible “on-site”.
Cancer impacts public health tremendously and the continuous growth of this impact is one of the primary factors driving the demand for point-of-care cancer screening during the forecast period. Increasing incidence of various cancer types across regions and high mortality rates due to cancer is also expected to fuel demand for point-of-care cancer screening. Increasing programs on awareness and comprehensive approach by various organizations for the prevention and control of cancer is also expected to contribute to the growth of point-of-care cancer screening market during the forecast period. Government-centered initiatives for point-of-care cancer screening, convenience of these screenings and cost effectiveness are also expected to boost demand for point-of-care cancer screening, globally. However, lack of awareness about point-of-care cancer screening in developing regions, stringent regulations regarding point-of-care cancer screening is expected to obstruct market growth for point-of-care cancer screening during the forecast period.
Based on screening type, Global Point-of-care cancer screening market is segmented as below:
- Genetic Screening
- Laboratory Screening
- Imaging Screening
- Biopsy Screening
- Pre-Endoscopy Screening
Based on cancer type, Global Point-of-care cancer screening market is segmented as below:
- Lung Cancer
- Breast Cancer
- Cervical Cancer
- Blood Cancer
- Kidney and Colorectal Cancer
- Prostate Cancer
Based on end use, Global Point-of-care cancer screening market is segmented as below:
- Diagnostic Centers
- Cancer Research Institutes
Improvements in point-of-care cancer screening regarding detection and more prudent characterization of biomarkers using range of biomarkers to include metabolites, lipids, RNA, or DNA, exosomes, or cells and detailed analysis of post-translational modifications might contribute to the development of better biomarker-based technologies for point-of-care cancer screening and pave the way for biomarkers in becoming the new gold-standard in point-of-care cancer screening. Global point-of-care cancer screening market is expected to witness a significant growth owing it to various R&D programs associated with point-of-care cancer screening. Certain regulations and safety updates are formulated by different health associations and government which is expected to fuel the point-of-care cancer screening market over the forecast period.
The point-of-care cancer screening market is projected to witness a robust growth in the North America region owing it to the increasing incidence of various forms of cancer and huge number of developmental companies present for point-of-care cancer screening manufacturing in the region. Asia-Pacific’s point-of-care cancer screening market and Europe’s market for Point-of-care cancer screening is also expected to grow at a significant rate during the forecast period due to growing awareness on the cost-effectiveness of point-of-care cancer screening tests. Increase in healthcare expenditure and improved healthcare infrastructure in also expected to propel market demand for point-of-care cancer screening in these regions. MEA point-of-care cancer screening market is expected to witness decent growth owing it to the poor healthcare infrastructure and low awareness about point-of-care cancer screening.
Some of the market participants in the Global point-of-care cancer screening market identified across the value chain include Hologic Corporation, Abbott Laboratories, Qiagen N.V., and F Hoffmann-La Roche, BD, Quest Diagnostics, OncoHealth Corp, Danaher, NOVIGENIX SA, and Quidel Corporation.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The report covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Argentina, Mexico, Brazil)
- Europe (Germany, Italy, U.K, Spain, France, Russia, Poland)
- Asia Pacific Excluding Japan (India, Australia & New Zealand, China, ASEAN)
- Middle East and Africa (GCC, South Africa, Rest Of MEA)
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint.